BeStock  
Stocks › Biotechnology › HALO

Halozyme Therapeutics HALO

US equityMarket cap rank #1380Biotechnology
$91.35 −$1.69 (-1.82%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $91.35 0.00%
Open$93.64
Prev close$93.04
Day range$90.79 – $93.64
Volume1.50M
Market cap$10.41B
P/E (TTM)22.8
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings22.8x
CheapRich

Above its usual level · 65th percentile, 5-year average 21.1x

#1903 of 2996 stocks by PE (1 = cheapest)

Price / book-188.4x
CheapRich

Near the bottom of its 5-year range · 1st percentile, 5-year average 38.1x

#5286 of 5338 stocks by PB (1 = cheapest)

Price / sales5.8x
CheapRich

Near the bottom of its 5-year range · 7th percentile, 5-year average 8.2x

#4169 of 5161 stocks by PS (1 = cheapest)

P/E over five years

9x20x31x41xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$92.48
Price vs. fair value-1.2%Close to the estimate
Star rating★★★☆☆
Economic moatWide
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB -188.35 – 38.12 1% (cheaper than usual) #5286 of 5338 (1 = cheapest)
PE 22.84 9.28 21.10 65% (pricier than usual) #1903 of 2996 (1 = cheapest)
PS 5.78 4.91 8.18 7% (cheaper than usual) #4169 of 5161 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on HALO.

Sign in to join the discussion.

Scroll to Top